These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1003411)

  • 41. [INCREMENT]9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 and related aminoalkylindole analogs in rats.
    Järbe TU; Gifford RS; Zvonok A; Makriyannis A
    Behav Pharmacol; 2016 Apr; 27(2-3 Spec Issue):211-4. PubMed ID: 26397760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.
    Dar MS
    Brain Res; 2000 May; 864(2):186-94. PubMed ID: 10802025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands.
    Lu D; Guo J; Duclos RI; Bowman AL; Makriyannis A
    J Med Chem; 2008 Oct; 51(20):6393-9. PubMed ID: 18826296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
    McMahon LR; France CP
    Exp Clin Psychopharmacol; 2003 Nov; 11(4):286-93. PubMed ID: 14599262
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of unsaturated side-chain analogs of tetrahydrocannabinol on cytochromes P450.
    Bornheim LM
    Biochem Pharmacol; 2000 Oct; 60(7):955-61. PubMed ID: 10974204
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats.
    Malone DT; Taylor DA
    Behav Brain Res; 2006 Jan; 166(1):101-9. PubMed ID: 16143410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. QSAR analysis of Delta(8)-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency.
    Keimowitz AR; Martin BR; Razdan RK; Crocker PJ; Mascarella SW; Thomas BF
    J Med Chem; 2000 Jan; 43(1):59-70. PubMed ID: 10633038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relative potency of tetrahydrocannabinol derivatives on tonic immobility in chickens.
    Maser JD; Gallup GG; Thorn WR; Edson PH
    Pharmacol Biochem Behav; 1975; 3(6):1069-72. PubMed ID: 1223896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drugs derived from cannabinoids. 1. Nitrogen analogs, benzopyranopyridines and benzopyranopyrroles.
    Pars HG; Granchelli FE; Razdan RK; Keller JK; Teiger DG; Rosenberg FJ; Harris LS
    J Med Chem; 1976 Apr; 19(4):445-54. PubMed ID: 817019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats.
    Schramm-Sapyta NL; Cha YM; Chaudhry S; Wilson WA; Swartzwelder HS; Kuhn CM
    Psychopharmacology (Berl); 2007 May; 191(4):867-77. PubMed ID: 17211649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Variation of the alkyl side chain in delta 8-THC.
    Huffman JW; Lainton JA; Dai D; Jordan RD; Duncan SG
    Life Sci; 1995; 56(23-24):2021-4. PubMed ID: 7776827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel uracil derivatives: newly synthesized centrally acting agents.
    Imaizumi M; Kano F; Sakata S
    Chem Pharm Bull (Tokyo); 1992 Jul; 40(7):1808-13. PubMed ID: 1394696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An investigation into the structural determinants of cannabinoid receptor ligand efficacy.
    Griffin G; Wray EJ; Rorrer WK; Crocker PJ; Ryan WJ; Saha B; Razdan RK; Martin BR; Abood ME
    Br J Pharmacol; 1999 Apr; 126(7):1575-84. PubMed ID: 10323589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthetic cannabinoids: the hidden side of Spice drugs.
    Pintori N; Loi B; Mereu M
    Behav Pharmacol; 2017 Sep; 28(6):409-419. PubMed ID: 28692429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction between delta-9-tetrahydrocannabinol and indomethacin.
    Green K; Kearse EC; McIntyre OL
    Ophthalmic Res; 2001; 33(4):217-20. PubMed ID: 11464074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. (-)-8beta-hydroxymethyl-delta1-tetrahydrocannabinol: a novel physiologically active analog of delta1-tetrahydrocannabinol.
    Razdan RK; Howes JF; Uliss DB; Dalzell HC; Handrick GR; Dewey WL
    Experientia; 1976 Apr; 32(4):416-7. PubMed ID: 1269636
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats.
    Wiley JL; O'connell MM; Tokarz ME; Wright MJ
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1097-105. PubMed ID: 17172531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.
    Solinas M; Scherma M; Tanda G; Wertheim CE; Fratta W; Goldberg SR
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1127-34. PubMed ID: 17351107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
    Rodríguez de Fonseca F; Rubio P; Menzaghi F; Merlo-Pich E; Rivier J; Koob GF; Navarro M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):56-64. PubMed ID: 8558457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats.
    Rubino T; Sala M; Viganò D; Braida D; Castiglioni C; Limonta V; Guidali C; Realini N; Parolaro D
    Neuropsychopharmacology; 2007 Sep; 32(9):2036-45. PubMed ID: 17287821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.